In this context, the observation that FPR2 agonists and NOX modulate SLC7A11/xCT expression and activity provides alternative possibilities to control the cystine/glutamate antiport and thus to develop new therapeutical strategies for the treatment of human cancers. This evidence concerns the gene SLC7A11 and cancer.